Early Diagnosis for Children with Cerebral Palsy: Clinical Effectiveness and Guidelines
SUMMARY OF ABSTRACTS

Early Diagnosis for Children with Cerebral Palsy

**Authors:** Kelsey Seal, Lorna Adcock


**Acknowledgments:**

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials. This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.
Research Questions

1. What is the clinical effectiveness of early diagnosis in children with cerebral palsy?
2. What are the evidence-based guidelines addressing early diagnosis in children with cerebral palsy?

Key Findings

Five systematic reviews, one with meta-analysis, one randomized controlled trial, and one non-randomized study were identified regarding the clinical effectiveness of early diagnosis in children with cerebral palsy.

Methods

A limited literature search was conducted on key resources including Ovid Medline, PubMed, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases and a focused Internet search. No methodological filters were applied to limit retrieval by publication type. The search was limited to English language documents published between January 1, 2016 and January 2, 2018. Internet links were provided, where available.

Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

<table>
<thead>
<tr>
<th>Population</th>
<th>Children with cerebral palsy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Early diagnosis</td>
</tr>
</tbody>
</table>
| Comparator          | Q1: Standard care; no comparator  
                      | Q2: No comparator             |
| Outcomes            | Q1: Clinical evidence of health benefits and/or harms e.g., earlier intervention; improved health, physical/cognitive function, neuroplasticity, etc.  
                      | Q2: Guidelines                |
| Study Designs       | Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, evidence-based guidelines |
Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, and evidence-based guidelines.

Five systematic reviews, one with meta-analysis, one randomized controlled trial, and one non-randomized study were identified regarding the clinical effectiveness of early diagnosis or intervention in children with cerebral palsy. No evidence-based guidelines were identified.

Additional references of potential interest are provided in the appendix.

Overall Summary of Findings

Five systematic reviews,\(^1\text{–}^5\) one with meta-analysis,\(^2\) were identified regarding the clinical effectiveness of early diagnosis in children with cerebral palsy (CP). One systematic review (SR)\(^1\) evaluated the level of evidence of vision interventions and assessments for infants 0-2 years of age at high risk or with a CP diagnosis. It found strong levels of evidence for neuroprotective interventions such as caffeine and hypothermia, but weak levels of evidence for surgery, visual training, or developmental programs. Another SR\(^2\) examined the diagnostic ability of early magnetic resonance imaging (MRI) to examine motor outcomes or CP in infants. The study reported that early MRI has reasonable sensitivity and specificity to detect adverse motor outcomes or CP, but further studies are needed to determine the clinical utility of early MRI. One SR\(^3\) evaluated the evidence on interventions applied during the first postnatal year in infants with, or at very high risk of CP; it also examined whether the type and dosing of intervention modifies the effect of intervention. The study reported that sufficient quality literature on early intervention is limited and provides weak evidence on the effect of the intervention. Another SR\(^4\) examined early, accurate diagnosis of CP. It reported that before 5 months of age, term-age MRI, Prechtl Qualitative Assessments of General Movements, and the Hammersmith Infant Neurological Examination are the most predictive tools for detecting risk of CP. After 5 months of age, MRI, the Hammersmith Infant Neurological Examination, and the Developmental Assessment of Young Children are the most predictive tools. Another SR\(^5\) reviewed the evidence on the effectiveness of motor interventions for infants (up to 2 years old) with a high risk or diagnosis of CP. The study reported there is some evidence that early intervention incorporating child-imitated movement, parental education, and environment modification have a positive effect on motor development, but published studies are limited and lack high-quality.

One randomized controlled trial\(^6\) and one non-randomized study\(^7\) were identified regarding the clinical effectiveness of early diagnosis in children with CP. The randomized controlled trial (RCT)\(^6\) randomly assigned infants with CP younger than 12 months to receive either baby constraint-induced movement therapy (CIMT) or baby massage. It was reported that baby CIMT appeared to improve the unimanual ability of young children with CP more than massage. The non-randomized study (NRS)\(^7\) evaluated the ability of Structured Observation of Motor Performance in Infants (SOMP-I) to detect CP in infants. The study reported that SOMP-I was sensitive for detecting CP early in infants, but the chosen cut-off can lead to false positives for CP.
References Summarized

Health Technology Assessments

No literature identified.

Systematic Reviews and Meta-analyses

   PubMed: PM28918222

   PubMed: PM29193032

   PubMed: PM27925172

   PubMed: PM28715518

   PubMed: PM27027732

Randomized Controlled Trials

   PubMed: PM29175749

Non-Randomized Studies

   PubMed: PM28728014

Guidelines and Recommendations

No literature identified.
Appendix — Further Information

Previous CADTH Reports


Systematic Reviews – Alternative Interventions


Non-Randomized Studies – Alternative Outcome


Additional References